Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer

Multicenter Phase II Study Evaluating Gemcitabine and Oxaliplatin in the Treatment of Patients Suffering From Metastatic Breast Cancer Who Are Not Candidates For Treatment With Antracyclines and Taxanes

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00274859

Enrollment

Registered

2006-01-11

Start date

2005-08-31

Completion date

Unknown

Last updated

2008-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Keywords

unspecified adult solid tumor, protocol specific

Brief summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with oxaliplatin works in treating patients with metastatic cancer who cannot receive anthracycline or taxane therapy.

Detailed description

OBJECTIVES: Primary * Determine the objective response rate in patients with metastatic cancer not amenable to anthracycline or taxane therapy treated with gemcitabine hydrochloride and oxaliplatin. Secondary * Determine the clinical benefit and tolerability of this regimen in these patients. * Determine the progression-free and overall survival of patients treated with this regimen. OUTLINE: This is an open-label, multicenter study. Patients receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically. PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study.

Interventions

DRUGgemcitabine hydrochloride

DRUGoxaliplatin

Study design

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed cancer * Metastatic disease * Measurable metastatic disease ≥ 1 cm by spiral CT scan and/or cutaneous lesion ≥ 2 cm * Not a candidate for anthracycline or taxane chemotherapy * No brain metastases PATIENT CHARACTERISTICS: * ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100% * Life expectancy \> 12 weeks * Neutrophil count \> 1,000/mm\^3 * Platelet count \> 100,000/mm\^3 * Alkaline phosphatase \< 5 times upper limit of normal (ULN) * Bilirubin \< 1.5 times ULN * Creatinine \< 1.5 times ULN OR creatinine clearance \> 30 mL/min * SGOT and SGPT \< 3 times ULN (5 times ULN if liver metastases present) * No pre-existing neuropathy * Not pregnant or nursing * No uncontrolled hypercalcemia * No familial, social, geographical, or psychological condition that would preclude study treatment * No other malignancy that is not considered cured PRIOR CONCURRENT THERAPY: * No prior chemotherapy for metastatic disease, including anthracyclines or taxanes * Prior hormonal therapy allowed

Design outcomes

Primary

Measure	Time frame
Objective response rate	—

Secondary

Measure	Time frame
Clinical benefit	—
Tolerability	—
Progression-free	—
Overall survival	—

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026